The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Open accessAbstract
rom a clinical perspective, type 2 diabetes mellitus might also be regarded as a vascular disease, characterized by increased arterial stiffness.Empagliflozin is a selective sodium-glucose cotransporter 2 inhibitor shown to improve glycemic control after short-and long-term treatment.1 In the EMPA-REG OUTCOME study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), a prospective randomized double-blind study in patients with type 2 diabetes mellitus with established cardiovascular disease, treatment with empagliflozin reduced the primary combined cardiovascular end point (3P-MACE [3-point major adverse cardiovascular event]), as well as secondary end points of hospitalization because of heart failure, cardiovascular morbidity, total mortality, and renal end points.2 We tested the hypothesis that improvements of vascular function and stiffness are involved in the observed improved cardiovascular and renal outcomes with empagliflozin treatment.In this investigator-initiated prospective, double-blind, randomized, placebocontrolled, crossover, interventional single-center trial, 76 female and male patients (18-75 years of age) with diagnosed type 2 diabetes mellitus were randomized to either empagliflozin 25 mg orally once daily or placebo for 6 weeks, followed by the second 6-week treatment with the other compound (crossover).In 64 patients, any antidiabetic agent was withdrawn 4 weeks before the baseline examination.We analyzed the effects of empagliflozin on central hemodynamics and vascular function at baseline (untreated status), after 6 weeks with empafliflozin/placebo, and after another 6 weeks with the other compound.The study protocol was approved by the local ethics committee, and written informed consent was obtained.To measure central systolic pressure and central pulse pressure, radial artery waveforms were recorded by the SphygmoCor System (AtCor Medical), and corresponding central (aortic) waveforms were then automatically generated through a validated transfer function.3 During 24-hour ambulatory, daily-life conditions, brachial blood pressure (BP), and derived central (aortic) pressure curves (obtained through a validated transfer function) were assessed by the Mobilograph (IEM).4 Statistical analysis was performed in the per protocol population (N=71).All patients (59% males, 62±7 years of age) were white, and 10 patients had established cardiovascular disease.At baseline, HbA1c was 6.75±0.8%,body weight 89.2 kg, office BP 129±14/77±7.6mm Hg, and ambulatory BP 129±10/79±7.1 mm Hg.Compared with placebo, empagliflozin effected a decrease of HbA1c (-0.26±0.44%,P=0.001), fasting glucose (-24.9±26mg/dL, P<0.001), body weight (-1.08±1.5 kg, P<0.001), brachial office BP (-5.20±7.8/-1.70±6.1 mm Hg, P<0.001/P=0.021),and 24-hour ambulatory BP (-2.13±7.3/-1.93±5.1 mm Hg, P=0.017/0.002).No safety issues were noted throughout the study.Under office conditions, central systolic (primary objective) and central pulse were lower by 5.14 mm Hg (P<0.001) in the empagliflozin group than in the placebo group after 6 weeks of treatment (Figure).Accordingly, a decreased forward pressure wave amplitude and a reduced reflected pressure wave amplitude were
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citation
Cited by
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
Metadata
- Authors
- Striepe, K., Jumar, A., Ott, C., Karg, M. V., Schneider, M. P., Kannenkeril, D., & Schmieder, R. E.
- Venue
- Circulation
- Published
- 2017-09-19
- Volume
- 136
- Issue
- 12
- Pages
- 1167-1169
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2755863750
- Cited by
- 169
- References
- 2
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.